UNIO Biotech is focused on developing new therapeutic approaches for glioblastoma and pain management, particularly in areas where current treatments are inadequate or have significant side effects.
We design single domain antibodies (sdAB) - also known as nanobodies - with the potential to provide targeted pain relief. These nanobodies offer a promising alternative due to their specificity and ability to engage with pain pathways differently from traditional therapies.
We have developed multiple drug candidates modeled after mitragynine pseudoindoxyl, a compound derived from the kratom leaf. These analogues are designed to deliver pain relief while minimizing the risk of addiction, addressing a key issue associated with opioid-based therapies.
We are developing several drug candidates inspired by compounds found in the Kanna plant, known for their potential to alleviate symptoms of major depressive disorder. These compounds aim to offer effective treatment with fewer side effects compared to traditional antidepressants, addressing a significant challenge in current mental health therapies.
We have developed a series of drug candidates targeting bromodomain and extra-terminal domain (BET) proteins, which play a critical role in regulating gene expression in cancer cells. These inhibitors are designed to disrupt key transcriptional programs that drive the growth of aggressive tumors, such as glioblastoma and other cancers of the brain. By selectively inhibiting BET proteins, our compounds aim to reduce tumor proliferation and enhance the effectiveness of existing therapies, providing a novel approach to combating treatment-resistant cancers.
We are developing a range of next-generation checkpoint inhibitors designed to enhance the immune system's ability to recognize and destroy cancer cells. Our candidates focus on overcoming immune suppression in the tumor microenvironment, targeting novel checkpoints beyond PD-1 and CTLA-4, including LAG-3 and TIM-3. These inhibitors are being developed to address tumors like glioblastoma, which are notoriously difficult to treat, by reactivating the body's natural immune response and improving the effectiveness of other immunotherapies.
UNIO BIOTECH